Macular oedema (diabetic) - aflibercept: committee papers

Table of Contents


01 Pre-Meeting Briefing prepared by NICE

02 Submission from the technology manufacturer - BAYER

03 NICE request to the manufacturer for clarification on their submission

04 Manufacturer clarification response

05 Consultee submission - Royal College of Ophthalmologists

05 Diabetes UK, Macular Society and Royal National Institute of Blind People - Joint submission

06 Clinicalexpert personal perspective -Sivaprasad

06 Patient expert personal perspective -Worrall

07 Evidence Review Group report prepared by Aberdeen HTA Group

08 Manufacturer factual accuracy check of Evidence Review Group report

09 Erratum to the Evidence Review Group report

10 Evidence Review Group exploratory analysis

This page was last updated: 28 May 2015